Stellar Biotechnologies, which makes a key protein used in the development of a number of immunotherapies, is expanding its manufacturing facility at Port of Hueneme in California. More: Stellar Biotech starts expansion project at its protein production plant Source: fierce
read moreDespite Roche’s insistence that the deaths of five patients taking its Hemlibra for hemophilia were not related to the drug, concerns arose on Wall Street that the news could stifle growth of the new product, which analysts had expected to
read moreBoehringer Ingelheim is looking to expand its compound nintedanib to treat some scleroderma patients. And in preparation, it’s looking to expand awareness about the disease, too. More: Boehringer Ingelheim taps Facebook Live to spread scleroderma awareness Source: fierce
read moreJockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year. That 51% average cut stemmed from 9.7% list-price hikes that sank to 6% after wheeling and dealing with
read moreTakeda is weighing a potentially difficult buyout bid for Shire that could be worth $52 billion, WuXi AppTec wins approval for its $900 million-plus IPO in Shanghai, Aslan Pharma aims to raise $86 million through an IPO on Nasdaq and
read moreCelgene’s stock has taken a beating in recent months, thanks to a string of bad news. But the company’s situation isn’t quite as dire as its share price indicates, one analyst insists. More: Relax, Celgene investors. The situation isn't as
read more© 1994 - 2024 B.M. Pharmaceuticals